5 IVT Design Considerations Before Scale-Up

When your RNA program moves from research into process development, the IVT reaction you optimized for yield may not be the one that holds up at scale. This article outlines five design considerations to evaluate before that transition, covering RNA polymerase behavior, input efficiency, byproduct formation, and processivity as upstream variables that shape downstream outcomes.

Rather than treating scale-up as a straightforward expansion, the article encourages you to examine the assumptions built into your early IVT work, including how your enzyme affects initiation and elongation, and whether your current process can meet tighter quality expectations with larger batch sizes. After reading, map each of the five considerations against your current IVT setup and identify where your process carries unexamined risk.

This kind of structured review, done before scale-up rather than after, can reduce costly troubleshooting during process development and support a cleaner path toward clinical manufacturing.